Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces mortality and morbidity in patients with chronic heart failure (HF). However, the clinical implication of SGLT2i therapy in patients with acute decompensated HF remains uncertain. We prospectively studied 86 type 2 diabetic mellitus (T2DM) patients (71.8 ± 12.1 years, 55 men) who were hospitalized for acute decompensated HF and received SGLT2i during the index hospitalization. Among the patients, 56 continued SGLT2i at discharge and 30 did not. The continued group experienced fewer HF re-hospitalizations than the discontinued group (24% versus 39%, P = 0.008) with a hazard ratio of 0.29 (95% confidence interval 0.10-0.85) adjusted for other significant potential confounders. In conclusion, long-term SGLT2i therapy might prevent unplanned HF re-hospitalization in patients with T2DM and acute decompensated HF.

钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 可降低慢性心力衰竭 (HF) 患者的死亡率和发病率。然而，SGLT2i 治疗对急性失代偿性 HF 患者的临床意义仍不确定。我们前瞻性研究了 86 名 2 型糖尿病 (T2DM) 患者（71.8 ± 12.1 岁，55 名男性），他们因急性失代偿性 HF 住院并在住院期间接受了 SGLT2i。在这些患者中，56 人在出院时继续使用 SGLT2i，30 人没有。与停药组相比，继续治疗组经历的 HF 再住院次数更少（24% 对 39%，P= 0.008），风险比为 0.29（95% 置信区间 0.10-0.85），针对其他重要的潜在混杂因素进行了调整。总之，长期 SGLT2i 治疗可能会防止 T2DM 和急性失代偿性 HF 患者出现意外的 HF 再住院。